Latest news with #IBS-D
Time of India
2 days ago
- Business
- Time of India
Trump's prescription drug price cuts unlikely to hit Indian pharma exports significantly: Crisil Ratings
US President Donald Trump 's executive order on reducing prescription drug prices will have a limited impact on Indian pharma companies, according to a report by Crisil Ratings . Citing the reason behind its observation, the credit rating firm in its report said that despite India exporting over half of its pharmaceutical output, the bulk comprises low-priced generic drugs, which already operate on razor-thin margins, leaving little room for further price cuts to materially affect revenues. In over half of the pharmaceutical output, one-third goes to the United States. India exports 54 per cent of its pharmaceutical production, of which nearly a third is to the US. Around 85 per cent of the exports to the US comprise formulations, largely generics, while sales from biosimilars and innovator drugs remain low. Also Read: US FDA approves Moderna's next-gen COVID vaccine for adults 65 or older Generic pharma drugs account for 90 per cent of the prescription sales volume but only 13 per cent of the value spending in the US. Generic drug prices in the US are very low and have lower prices in comparison to economically peer countries. Live Events The executive order issued in the United States aims to reduce the prices of prescription drugs by 30-80 per cent through the adoption of a Most Favoured Nation (MFN) pricing model. The US Department of Health and Human Services (HHS) has outlined the initial steps to be taken to implement this policy, involving identification of manufacturers expected to align the prices of branded products, which do not currently have generic or biosimilar competition, with the lowest price among a set of economic peer countries of the US. Trump's executive order primarily targets high-margin branded innovator drugs and excludes generics and biosimilars. "The MFN model is unlikely to significantly affect the bulk of India's exports," the report added. Also Read: Zydus gets USFDA nod for generic IBS-D treatment drug It further added, "However, potential indirect impact, through lower growth prospects for upcoming generic versions of innovator drugs going off patent, due to lower price differential post price reductions of the innovator drugs, would bear watching." However, a few formulation companies with niche presence in the branded innovator drug segment can face some pricing risk. "API exports (15 per cent of India's pharma exports) are expected to be broadly unaffected, as it is not a major cost for high-margin originator drugs, abating concerns of pricing pressure," the report added. Additionally, the policy may create opportunities for contract manufacturing organisations, which constitute 8 per cent of India's pharma market. "The policy may create opportunities for CMOs ( 8 per cent of India's pharma market), with orders expected to improve as global pharma companies seek to lower production costs by outsourcing. While this could support volumes, the pressure on pricing may result in renegotiation of contract rates, compressing margins," the report further added.
The Hindu
3 days ago
- Business
- The Hindu
Zydus gets U.S. FDA tentative nod for Rifaximin tablets 550 mg
Generic drugmaker Zydus Lifesciences has received tentative approval from the U.S. Food and Drug Administration (FDA) for Rifaximin Tablets, 550 mg. The product is indicated for treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults. Rifaximin tablets had annual sales of $2672.9 million in the United States, the company said citing IQVIA MAT March 2025 numbers. The product will be produced at the Group's manufacturing site at SEZ II, Ahmedabad, it said on Monday.
Time of India
3 days ago
- Business
- Time of India
Zydus gets USFDA nod for generic IBS-D treatment drug
Zydus Lifesciences on Monday said it has received approval from the US health regulator to market a drug for the treatment of irritable bowel syndrome with diarrhoea in adults. The company has received tentative approval from the US Food and Drug Administration (USFDA) for Rifaximin Tablets (550 mg), the drug manufacturing firm said in a regulatory filing. Rifaximin tablets are indicated for the treatment of irritable bowel syndrome with diarrhoea ( IBS-D ) in adults. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Access all TV channels anywhere, anytime Techno Mag Learn More Undo As per the IQVIA MAT March sales data, Rifaximin tablets had an annual sales of USD 2,672.9 million in the US. Shares of Zydus Lifesciences were trading at Rs 926.05 apiece, 0.41 per cent down from previous close, on BSE.
Business Upturn
4 days ago
- Business
- Business Upturn
Zydus receives tentative USFDA approval for Rifaximin Tablets, 550 mg
By Aman Shukla Published on June 2, 2025, 08:12 IST Zydus Lifesciences Limited, along with its subsidiaries and affiliates (collectively referred to as 'Zydus'), has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Rifaximin Tablets, 550 mg. The approved product is a generic version of Xifaxan® Tablets, 550 mg, which is indicated for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults. The tablets will be manufactured at the company's SEZ II facility in Ahmedabad, India. According to IQVIA MAT data for March 2025, Rifaximin Tablets, 550 mg, recorded annual sales of approximately USD $2,672.9 million in the U.S. market. With this tentative approval, Zydus now has a total of 427 ANDA approvals. Since beginning its ANDA filings in the financial year 2003–04, the company has submitted 492 ANDAs to date. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Hindustan Times
24-04-2025
- Health
- Hindustan Times
IBS Awareness Month: More than just a tummy trouble
It's time we start paying attention to something that's been quietly impacting millions — Irritable Bowel Syndrome, or IBS. Unlike conditions that show up on scans or blood tests, IBS doesn't always leave visible signs, but for those who live with it, the discomfort is very real. Bloating, stomach cramps and unpredictable bathroom habits aren't just 'in your head' — they're part of a complex gut disorder that's all too often misunderstood or ignored. According to Telangana's Pace Hospitals, 4 to 7% of people in India are living with IBS, and numbers are slowly but steadily rising. That's why the theme for 2025's IBS Awareness Month — More Than A Stomachache — couldn't be more timely. Because let's face it, IBS is not just about digestion. It can take a serious toll on your self-confidence, your mental well-being, and your overall quality of life. There are multiple types of IBS: IBS-C (with constipation as the main symptom), IBS-D (dominated by diarrhoea), and IBS-M (a mix of both — sometimes constipation, sometimes diarrhoea, making it harder to manage). And while we often link flare-ups to poor diet or stress — both valid triggers — the truth is, IBS behaves differently in every person. It's complex, it's frustrating, and unfortunately, it's still stigmatised. One gentle trend that's been making its way into everyday wellness routines — especially among Gen Z — is the rise of digestive drinks. These herbal concoctions, often made from everyday ingredients like jeera (cumin), ajwain (carom seeds), fennel, ginger, mint, and lemon, are gaining popularity for their soothing effects on the gut. Celebs are part of the wave, too. Actor Alaya F recently shared her go-to morning gut tonic, while Malaika Arora and Jennifer Aniston have also opened up about drinks they swear by to keep their digestion in check. But is there real science behind these wellness elixirs? Or is this just another trend dressed in wellness clothing? Alaya F's ayurvedic drink Her morning mix includes ajwain, cumin, fennel, ginger, fresh mint, and soaked basil (sabja) seeds — all steeped in warm water overnight. Taken on an empty stomach, it's meant to soothe bloating and kick-start digestion. Especially helpful for those with IBS-D (the diarrhoea kind). Malaika Arora's clove tea Malaika prefers clove-infused water, which is known for its anti-inflammatory properties. This one's great for easing general discomfort and might help those with IBS-D too, but less effective for constipation. Steep a few cloves in hot water, drink. Jennifer Aniston's colostrum kick Her go-to is a drink made with bovine colostrum (yes, the first milk from cows post-birth), lemon juice, ginger, and sometimes Manuka honey. High in immune-supporting nutrients, this one's geared more towards IBS-C symptoms and overall gut immunity. Many of the ingredients found in digestive drinks aren't just kitchen staples — they're backed by science. Ginger helps the gut move more efficiently and eases inflammation. Peppermint has a naturally calming effect, chamomile soothes spasms and fennel and mint can ease bloating. Lemon juice is known to kick-start digestive enzymes, while probiotics and prebiotics nourish the gut's good bacteria. 'These are ingredients most of us already have at home,' says Dr Bir Singh Sehrawat, Program Clinical Director and Head of Gastroenterology at Marengo Asia Hospitals, Faridabad, adding, 'These celeb drinks support digestion, relieve gas and bloating, and encourage regular bowel movements. Something as simple as lemon and honey in warm water can help clear the stomach first thing in the morning.' But while these drinks may offer comfort in the early stages of IBS or when symptoms are mild, they're not a fix for everything. If symptoms become more serious — unexplained weight loss, ongoing diarrhoea or constipation, or blood in stools — it's time to see a doctor. 'In such cases, medical attention and a tailored treatment plan are essential,' he adds. Samiksha Kalra Gupta, Head of the Dietetics Department at Madukar Rainbow Children's Hospital, agrees and adds, 'Digestive drinks are not a replacement for medical treatment for IBS. Individuals with IBS should work closely with their healthcare provider to develop a comprehensive management plan.' Food: Dr Piyush Ranjan recommends the low-FODMAP diet, which has been shown to reduce IBS symptoms in many. Including fibre-rich foods, fermented items like curd and pickles, and avoiding known personal triggers (like dairy or certain veggies) can be helpful. Sleep: A chaotic sleep schedule can mess with your gut more than you'd think. Poor sleep slows digestion and increases inflammation. Setting a consistent bedtime — and avoiding heavy late-night meals — can help. Stress: The gut-brain connection is real. Anxiety and stress can worsen IBS symptoms. Mindful activities like yoga, deep breathing, or even a casual walk can help calm the nervous system and, in turn, your gut. Hydration: Water is your gut's best friend. So are herbal teas, and fruits like watermelon or cucumber that offer hydration and fibre. Movement: Exercise helps everything — digestion included. You don't need a HIIT routine. Even walking or stretching regularly can improve bowel movement and reduce bloating.
